ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0453

Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family

Andrea Pluma1, Linda Rüegg2, Sabrina Hamroun3, Axel Finckh4, Yvette Meissner5 and Frauke Foerger6, 1Vall d'Hebron University Hospital, Barcelona, Spain, 2Inselspital, Bern University Hospital, Bern, Switzerland, 3Cochin University Hospital, Paris, Ile-de-France, France, 4Geneva University Hospital, Geneva, Switzerland, 5Deutsches Rheuma-Forschungszentrum, Berlin, Germany, 6University hospital Bern /Inselspital Bern, Bern, Switzerland

Meeting: ACR Convergence 2024

Keywords: Biologicals, Disease Activity, pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Counselling patients with rheumatic and musculoskeletal diseases (RMD) in the phase of reproduction, pregnancy and breastfeeding is a challenging task. The potential risk of drug therapy must be weighed against the risk of untreated RMD for the patient and the risk of fertility issues and unfavourable pregnancy outcomes. Therefore, inactive disease is the treatment target and the prerequisite for improved outcomes. Given the limited amount of high quality data on many anti-rheumatic drugs, we analysed the extent to which drug recommendations in daily practice may be related to considerations of disease activity.

Methods: The current EULAR task force on antirheumatic drugs in reproduction, pregnancy and lactation includes 21 international experts prescribing drugs. In December 2023 these experts were asked to fill in a web-based questionnaire similar to the one used for the 2016 EULAR points to consider for use of antirheumatic drugs in pregnancy and breastfeeding [1]. The questionnaire addressed drug use before or during pregnancy, during breastfeeding and in male patients planning to conceive. For each drug, the expert had to choose one of the four options: (1) recommend the drug in the same way as if the patient was not pregnant / breastfeeding / planning to conceive, (2) only recommend the drug if one feared at least moderate or (3) severe disease in its absence, or (4) would never recommend the drug in pregnancy / while breastfeeding / in a male patient planning to conceive.
[1] Gotestam Skorpen C et al. Ann Rheum Dis. 2016 May;75(5):795-810.

Results: The expert opinion on the use of drugs in women before and during pregnancy (Figure 1A) showed that the majority recommended pregnancy-compatible csDMARDs, the TNFi certolizumab and IVIG in the same way as if the patient was not pregnant. The use of other TNFi and non-TNFi biologics in pregnant women was primarily recommended if there was a risk of moderate or severe disease activity without the drug. Similarly, experts recommended NSAIDs and oral glucocorticoids almost exclusively for the control of active disease states.

In breastfeeding women TNFi and other biologics, compatible csDMARDs, NSAIDs and oral glucocorticoids were most often recommended in the same way as if the patient did not breastfeed (Figure 1B).

In male patients planning to conceive most antirheumatic drugs were recommended in the same way as outside family planning (Figure 1C).

Conclusion: Experts in the field base their recommendations for the use of antirheumatic drugs in women before and during pregnancy primarily on the evidence of drug safety and the potential risk of active disease for the mother and the fetus. The expert’s risk benefit analysis is most obvious for the recommendations on the use of biologics in women planning a family. On the other hand, a more permissive recommendation of antirheumatic drugs is possible for breastfeeding women and men planning to conceive due to the absence of fetal exposure.

Supporting image 1

Expert opinion on use of antirheumatic drugs in women before or during pregnancy, in breastfeeding women, and in male patients planning to conceive
Among the current EULAR task force, 21 experts were drug prescribers and replied to a survey on drug use in women before and during pregnancy, breastfeeding women and male patients planning to conceive.
A) Answers to the question about drug use before or during pregnancy: What would you recommend to a woman under this medication who wants to conceive or already has a positive pregnancy test?

Supporting image 2

B) Answers to the question about drugs during breastfeeding: What would you recommend a woman under this medication who wants to breastfeed?

Supporting image 3

C) Answers to the question about drugs in male patients planning to conceive: What would you recommend a male patient under this medication who wants to conceive?


Disclosures: A. Pluma: None; L. Rüegg: None; S. Hamroun: None; A. Finckh: None; Y. Meissner: None; F. Foerger: None.

To cite this abstract in AMA style:

Pluma A, Rüegg L, Hamroun S, Finckh A, Meissner Y, Foerger F. Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/risk-of-active-disease-determines-the-expert-opinion-use-of-biologics-in-pregnancy-but-less-in-breastfeeding-and-in-men-planning-a-family/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-active-disease-determines-the-expert-opinion-use-of-biologics-in-pregnancy-but-less-in-breastfeeding-and-in-men-planning-a-family/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology